Yuxi Walvax Biotechnology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary, Public
- Established
- 2001-01-16
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.walvax.com
Clinical Trials
8
Active:1
Completed:4
Trial Phases
3 Phases
Phase 1:3
Phase 3:4
Phase 4:1
Drug Approvals
3
PHILIPPINES:3
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (50.0%)Phase 1
3 (37.5%)Phase 4
1 (12.5%)A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
Phase 3
Active, not recruiting
- Conditions
- Pneumococcal Disease, Invasive
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 630
- Registration Number
- NCT05934890
- Locations
- 🇮🇩
RSUP Prof. Dr. I.G.N.G Ngoerah, Denpasar, Bali, Indonesia
🇮🇩Ilmu Kesehatan anak FKUI RSCM, Jakarta Pusat, Jakarta, Indonesia
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
Phase 1
- Conditions
- COVID-19
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05396573
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
Phase 1
Not yet recruiting
- Conditions
- COVID-19
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05394012
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Phase 3
- Conditions
- SARS-CoV-2COVID-19
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 28000
- Registration Number
- NCT04847102
- Locations
- 🇮🇩
Persahabatan Hospital, Jakarta, Indonesia
🇮🇩Puskesmas Duren Sawit, Jakarta, Indonesia
🇮🇩Puskesmas Kalideres, Jakarta, Indonesia
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
Phase 4
Completed
- Conditions
- Neisseria Meningitides Meningitis
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT04450498
- Locations
- 🇲🇱
Centre pour le Développement des Vaccins du Mali, Bamako, Mali
- Prev
- 1
- 2
- Next
News
No news found